GO
Loading...

Abbott Laboratories

More

  • WASHINGTON, Nov 21- Keith Higgins, who runs the office that reviews public companies' books at the U.S. Securities and Exchange Commission, reported stock holdings worth between about $2 million and $6 million last year and the sale of stocks throughout 2014, according to SEC disclosures viewed by Reuters. Since the beginning of the year, he has reported about 60...

  • NEW YORK, Nov 19- Nearly a decade after losing a bidding war for device maker Guidant to Boston Scientific Corp, Johnson& Johnson finally has a chance for payback at a multibillion-dollar trial set to begin on Thursday. A federal court judge in New York will hear the case without a jury and decide whether Guidant, through its successor Boston Scientific, should be...

  • WASHINGTON, Nov 12- Republicans in the U.S. Congress will soon move to kill a medical device tax imposed less than two years ago under President Barack Obama's healthcare law, congressional aides and analysts said on Wednesday. Though no full-scale repeal of Obamacare is expected, even with the Senate now under Republican control, the move against the tax is part...

  • Republican knives out for Obama's medical devices tax Wednesday, 12 Nov 2014 | 5:25 PM ET

    Last week's elections will elevate Republican Senator Orrin Hatch, a long-standing opponent of the tax, to the chairmanship of the tax-writing finance committee in the Senate. Though no full-scale repeal of Obamacare is expected, even with the Senate under Republican control, the move against the device tax is part of efforts to chip away at the law.

  • AbbVie: Strong results lessen need for big deal Friday, 31 Oct 2014 | 12:46 PM ET

    AbbVie reported strong earnings on demand for its Humira drug and said it could deliver strong long-term growth without another big merger bid.

  • Oct 31- AbbVie, which this month abandoned its planned $55 billion purchase of Dublin drugmaker Shire, reported impressive quarterly earnings on demand for its Humira arthritis drug and said it could deliver strong long-term growth without rushing into another big merger attempt. "The underlying growth prospects of AbbVie don't require us to do a deal of that...

  • Oct 15- Another proposed U.S. corporate tax "inversion" deal collapsed on Friday when Irish food group Fyffes Plc and larger U.S. rival Chiquita Brands International Inc called off an agreement to combine. It was the fourth such deal to unravel since the Treasury Department on Sept. 22 cracked down on inversions, deals in which a U.S. company acquires or sets up a...

  • Oct 22- Abbott Laboratories and Mylan Inc said on Wednesday they would go ahead with their $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and set up headquarters in the Netherlands, but they tweaked the terms of the transaction. Treasury on Sept. 22 made changes to the corporate tax rules that govern such "inversion" merger...

  • Abbott says third-quarter sales match forecasts Wednesday, 22 Oct 2014 | 8:11 AM ET

    Oct 22- Abbott Laboratories said its third-quarter sales were in line with Wall Street forecasts and that it had slightly changed the terms of a deal to sell generic drugs to Mylan Inc.. Abbott on Wednesday said sales from continuing and discontinued operations rose 4.7 percent to $5.6 billion in the third quarter. That included generic medicines, now...

  • Earnings set to drive markets again Wednesday, 22 Oct 2014 | 5:55 AM ET
    Traders on the floor of the New York Stock Exchange.

    Earnings news will take center stage Wednesday after another day of strong stock market gains cemented the view that the worst is over.

  • Earnings set to take markets' center stage Tuesday, 21 Oct 2014 | 7:29 PM ET
    Traders on the floor of the New York Stock Exchange.

    Earnings news will take center stage Wednesday after another day of strong stock market gains cemented the view that the worst is over.

  • NEW YORK, Oct 20- AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and should remain at the helm of the Chicago drugmaker. Investors were given no advance warning on Thursday, when...

  • NEW YORK, Oct 20- AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and should remain at the helm of the Chicago drugmaker. Investors were given no advance warning on Thursday, when...

  • NEW YORK, Oct 20- AbbVie Chief Executive Officer Richard Gonzalez for three months led the charge to buy Dublin drugmaker Shire for $55 billion, only to walk away from the deal last week, but analysts and fund managers said he deserves credit for trying and should remain at the helm of the Chicago drugmaker. Investors were given no advance warning on Thursday, when...

  • AbbVie: $55B acquisition of Shire officially dead Monday, 20 Oct 2014 | 6:18 PM ET

    AbbVie will pay Shire a $1.64 billion breakup fee for walking away from the deal.

  • Oct 15- Major U.S. drugmaker AbbVie Inc said on Wednesday it was reconsidering a $55 billion bid for Ireland's Shire Plc, marking a setback for "inversion" deals in which U.S. companies reincorporate abroad to cut tax costs. Steris Corp said on Monday it has offered to buy Britain's Synergy Health Plc for about $1.9 billion in a deal that would shift Steris' tax...

  • LONDON, Oct 14- GlaxoSmithKline is seeking binding bids by next month for a range of older drugs worth more than $3 billion, which it is likely to sell by geographical region, according to people with direct knowledge of the process. Britain's biggest drug maker is looking to divest the mature products in a bid to improve its growth profile and wants to dispose of...

  • *Gas Natural to launch 4,700 peso per share bid for CGE. MADRID/ SANTIAGO, Oct 12- Spain's Gas Natural on Sunday said it would launch a $3.3 billion takeover offer for Chile's biggest electricity distributor Compania General de Electricidad, in a bid to boost its presence in growing Latin American markets. As part of the deal with those investors, Gas Natural will...

  • Cramer selloff plan: Surviving as stocks tumble Wednesday, 1 Oct 2014 | 6:08 PM ET

    The next leg of this market isn’t going to be easy. Cramer, however, has a plan.

  • *Action may deter Pfizer from returning to bid for AstraZeneca. WASHINGTON/ NEW YORK, Sept 23- Tough new U.S. rules on corporate "inversions" on Tuesday sent a chill through the market for the tax-avoidance deals, both pending and potential, with share prices falling sharply in nearly a dozen companies on both sides of the Atlantic.